[ad_1] LUND, Sweden, Nov. 28, 2024 /PRNewswire/ — Immunovia (STO: IMMNOV), the pancreatic cancer diagnostics company, will present at the Redeye Technology & Life Science Day on December 3, hosted by Redeye. Redeye Technology & […]
Tag: Immunovia AB
Immunovia presents model-development study results at meeting of the Collaborative Group of the Americas–Inherited Gastrointestinal Cancers
[ad_1] PHILADELPHIA, Nov. 15, 2024 /PRNewswire/ — Immunovia (NASDAQ Stockholm: IMMNOV), the pancreatic cancer diagnostics company, will present results from the recently completed model-development study of the company’s next-generation test at the 2024 annual meeting of […]
Immunovia presents data from model development study at meeting of the PRECEDE pancreatic cancer research consortium
[ad_1] SAN DIEGO, Nov. 7, 2024 /PRNewswire/ — Immunovia (NASDAQ STOCKHOLM: IMMNOV), the pancreatic cancer diagnostics company, will present an update on its next-generation test at the annual meeting of the PRECEDE Consortium, a collaboration […]
Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer
[ad_1] LUND, Sweden, Oct. 7, 2024 /PRNewswire/ — Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has acquired all blood samples required to clinically validate its next-generation test for […]
Immunovia has successfully acquired all blood samples required to clinically validate its next-generation test for pancreatic cancer
[ad_1] LUND, Sweden, Oct. 7, 2024 /PRNewswire/ — Immunovia (IMMNOV: Nasdaq Stockholm), the pancreatic cancer diagnostics company, today announces that the company has acquired all blood samples required to clinically validate its next-generation test for […]
